With our Science Talk blog, we hope to lift the lid on the black box that is the ICR: to show you inside our labs, to introduce you to a few of the people here who make the discoveries, and to allow ...
Need to find a specific expert or member of a research group or division? Just search by role, division, name or browse our researchers A-Z.
The dedication of these charities, set up when a family has been touched by cancer, drives forward our research immeasurably. We are so grateful to work with such passionate organisations and receive ...
PENELOPE B is a phase III international, multicentre, randomised, placebo-controlled, double-blind trial comparing the efficacy and safety of adding palbociclib to standard hormone therapy vs standard ...
These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...
Every day in the UK, about 1,000 people find out that they have cancer. Most of these people will end up sharing the news with family, friends and colleagues, from whom they will usually receive ...
A pioneering clinical trial has demonstrated for the first time that two existing treatments can be combined to potentially improve outcomes for sarcoma and melanoma patients with advanced tumours in ...
These findings have now been published in The Lancet. Cutting edge proton beam therapy is no better than intensity-modulated radiotherapy for treating people with head and neck cancer, according to ...
A spit test, where a sample can be collected at home, is more accurate at identifying future risk of prostate cancer for some men than the current standard PSA blood test, a new study reports. Results ...
The Institute of Cancer Research, London, has welcomed the approval of a new combination of two drugs for a rare form of ovarian cancer by the US regulatory body the Food and Drug Administration (FDA) ...
One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results